# Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07473128/  
OnCo record `nct07473128` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Trilaciclib in small-cell lung cancer, run by Pharmacosmos A/S, now recruiting.

## Summary

Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07473128 by Pharmacosmos A/S, with 120 participants planned, started 2026-06-30 and due to reach its primary completion in 2027-06. Interventions recorded: Trilaciclib, Saline (0.9% NaCl). Conditions listed: Limited Stage Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07473128
- Phase: 3
- Setting: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer
- Sponsor: Pharmacosmos A/S
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT07473128: https://clinicaltrials.gov/study/NCT07473128

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Trilaciclib](https://onco.cc/drugs/trilaciclib/)
- companies: [Pharmacosmos](https://onco.cc/companies/pharmacosmos/)

---
JSON: https://onco.cc/api/v1/entities/nct07473128.json